Event rate at short term follow up, number needed to treat, and events avoided per 1000 patients treated in randomised clinical trials comparing primary angioplasty and fibrinolysis.
| 30-day events | PTCA (%, n) | Lysis (%, n) | p Value | OR (95%CI) | ARR% | NNT | NEA × 1000 |
|---|---|---|---|---|---|---|---|
| *The SHOCK trial did not compare PTCA with lysis, but a strategy of emergency revascularisation versus initial medical stabilisation. | |||||||
| †Data not published. Presented at the scientific sessions of the American College of Cardiology, March 2002. | |||||||
| ‡Includes disabling stroke. | |||||||
| ARR, absolute risk reduction; NEA × 1000, number of events avoided per 1000 patients treated; NNT, number needed to treat. | |||||||
| Mortality | |||||||
| Weaver10 | 4.4%, 57/1290 | 6.5%, 86/1316 | 0.02 | 0.66 (0.46 to 0.94) | 2.1 | 47 | 21/1000 |
| GUSTO II-B7 | 5.7%, 32/565 | 7.0%, 40/573 | 0.37 | 0.80 (0.49 to 1.30) | 1.3 | 77 | 13/1000 |
| SHOCK8* | 46.7%, 71/152 | 56%, 84/150 | 0.11 | 0.83 (0.67 to 1.04) | 9.3 | 11 | 91/1000 |
| C-PORTw46 | 5.3%, 12/225 | 6.2%, 14/226 | 0.7 | Not available | 0.9 | 111 | 9/1000 |
| DANAMI-2† | 6.6%, 52/790 | 7.6%, 59/782 | 0.35 | Not available | 1.0 | 100 | 10/1000 |
| Mortality or non-fatal reinfarction | |||||||
| Weaver | 7.2%, 94/1290 | 11.9%, 156/1316 | <0.001 | 0.58 (0.44 to 0.76) | 4.7 | 21 | 48/1000 |
| GUSTO-IIB | 9.6%, 54/565 | 12.2%, 70/573 | 0.08 | 0.72 (0.49 to 1.05) | 3.1 | 32 | 31/1000 |
| C-PORT‡ | 9.8%, 22/225 | 16.8%, 38/226 | 0.03 | 0.52 (0.30 to 0.89) | 7 | 14 | 71/1000 |
| DANAMI-2†‡ | 8.0%, 63/790 | 13.7%, 107/782 | 0.0003 | Not available | 5.7 | 18 | 55/1000 |
| Stroke | |||||||
| Weaver | 0.7%, 9/1290 | 2.0%, 26/1316 | 0.007 | 0.35 (0.14 to 0.77) | 1.3 | 77 | 13/1000 |
| PAMIw27 | 0 | 3.5%, 7/200 | 0.01 | Not available | 3.5 | 29 | 34/1000 |
| Zijlstra16 | 0.7%, 1/152 | 2.0%, 3/149 | 0.6 | 0.32 (0.01 to 4.08) | 1.3 | 77 | 13/1000 |
| GUSTO II-B | 1.1%, 6/565 | 1.9%, 11/573 | 0.34 | 0.54 (0.17 to 1.63) | 0.8 | 125 | 8/1000 |
| C-PORT | 1.3%, 3/225 | 3.5%, 8/226 | 0.13 | Not available | 2.2 | 45 | 22/1000 |
| DANAMI-2† | 1.1%, 8/790 | 2.0%, 15/782 | 0.15 | Not available | 0.9 | 111 | 9/1000 |
| Haemorrhagic stroke | |||||||
| Weaver | 0.1%, 1/1290 | 1.1%, 15/1316 | <0.001 | 0.07 (0.0 to 0.43) | 1 | 100 | 10/1000 |
| PAMI | 0 | 2.0%, 4/200 | 0.05 | Not available | 2 | 50 | 20/1000 |
| Zijlstra | 0.7%, 1/152 | 1.3%, 2/149 | 0.98 | 0.49 (0.01 to 9.47) | 0.6 | 166 | 6/1000 |
| GUSTO-IIB | 0 | 1.4%, 8/573 | 0.007 | Not available | 1.4 | 71 | 14/1000 |